Chief Executive Officer (principal executive officer) · ALNYLAM PHARMACEUTICALS, INC. (ALNY)

MBChB Yvonne L. Greenstreet

A named executive officer of ALNYLAM PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$4,588,810

Salary $850,000Stock awards $0

FY2021: $8,575,220

2nd of 5 named executive officers at Alnylam Pharmaceuticals by FY2022 total.

5 named officers on file for ALNYLAM PHARMACEUTICALS, FY2022

MBChB Yvonne L. Greenstreet’s pay file — $29

  • 6 fiscal years of pay, line by line
  • ALNY’s disclosed peer group of 12 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ALNYLAM PHARMACEUTICALS’s whole pay program stands against its peers

  • ALNYLAM PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ALNY→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 3, 2023 (DEF 14A).

Free

Get MBChB Yvonne L. Greenstreet’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

MBChB Yvonne L. Greenstreet compensation by year

ALNYLAM PHARMACEUTICALS Summary Compensation Table · all 6 fiscal years held
In US dollars, as ALNYLAM PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2019FY2020FY2021FY2022
Salary$144,231$504,200$571,423$621,500$619,100$850,000
Bonus$100,000$0$0$0$0$0
Stock awards$0$0$460,360$0$0$0
Option awards$5,646,746$0$1,654,494$1,798,843$7,341,000$2,498,790
Non-equity incentive$56,000$327,730$370,875$434,736$429,120$977,500
Pension and deferred compensation$0$0$0$0$0$0
All other$40,379$152,744$192,874$178,922$186,000$262,520
Total$5,987,356$984,674$3,250,026$3,034,001$8,575,220$4,588,810

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ALNYLAM PHARMACEUTICALS, INC. DEF 14A filed April 3, 2023, accession 0001193125-23-089611, and prior-year filings.

How this page was built: the ALNYLAM PHARMACEUTICALS, INC. filed document, accession 0001193125-23-089611. Every figure is read from that document and cited to the page and table it appears in. Filed April 3, 2023.

$6.0M
$985K
$3.3M
$3.0M
$8.6M
$4.6M
FY16
FY17
FY19
FY20
FY21
FY22
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

ALNYLAM PHARMACEUTICALS’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Indrani FranchiniExecutive Vice President, Chief Legal Officer and Secretary$5,408,220
MBChB Yvonne L. Greenstreet · this pageChief Executive Officer (principal executive officer)$4,588,810
Akshay VaishnawPresident$3,591,620
Pushkal GargChief Medical Officer and Executive Vice President, Development & Medical Affairs$2,900,580
Jeffrey PoultonExecutive Vice President, Chief Financial Officer (principal financial officer)$2,421,630

Board service

ALNYLAM PHARMACEUTICALS board · FY2022–FY2025

How this board is paid

Company policy: ALNYLAM PHARMACEUTICALS pays directors a $60,000 cash retainer and $400,000 in 50% Stock Options, 50% RSUs. As stated in ALNYLAM PHARMACEUTICALS's FY2025 proxy.

The full ALNYLAM PHARMACEUTICALS compensation record

free company brief

This page is one person within ALNYLAM PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ALNYLAM PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ALNYLAM PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

MBChB Yvonne L. Greenstreet's compensation dossier · One-time report. No refunds.